Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akari Therapeutics (AKTX) Amortization (2015 - 2022)

Akari Therapeutics recorded quarterly Amortization of $20339.0 in Q4 2022, up 41.86% quarter-over-quarter from $14337.0 in Q4 2021, and up 41.86% year-over-year from $14337.0 in Q4 2021.

Akari Therapeutics' Amortization history runs 8 years deep, the most recent figure standing at $20339.0 for Q4 2022.

  • In Q4 2022, Amortization rose 41.86% year-over-year to $20339.0; the TTM figure through Dec 2022 stood at $20339.0 (up 41.86% YoY), while the FY2022 annual figure was $20339.0, up 41.86% from the prior year.
  • Amortization came in at $20339.0 for Q4 2022 at Akari Therapeutics, up from $14337.0 in the prior quarter.
  • In the past five years, Amortization ranged from a high of $20366.0 in Q4 2018 to a low of $9950.0 in Q4 2019.
  • A 5-year average of $16512.0 and a median of $17568.0 in 2020 frame the typical range for Amortization.
  • Across the five-year window, Amortization tumbled 51.14% in 2019 and jumped 76.56% in 2020, its largest moves.
  • Akari Therapeutics' Amortization stood at $20366.0 in 2018, then sank by 51.14% to $9950.0 in 2019, then soared by 76.56% to $17568.0 in 2020, then slipped by 18.39% to $14337.0 in 2021, then surged by 41.86% to $20339.0 in 2022.
  • According to Business Quant data, Amortization over the past three periods registered $20339.0, $14337.0, and $17568.0 for Q4 2022, Q4 2021, and Q4 2020 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortization (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -13.75 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Revolution Medicines 32.39 Bn 32.39 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 20,339.00
Dec 31, 2022 20,339.00
Dec 31, 2021 14,337.00
Dec 31, 2021 14,337.00
Dec 31, 2020 17,568.00
Dec 31, 2020 17,568.00
Dec 31, 2019 9,950.00
Dec 31, 2019 9,950.00
Dec 31, 2018 20,366.00
Dec 31, 2018 20,366.00
Dec 31, 2017 41,526.00
Dec 31, 2017 41,526.00
Dec 31, 2016 49,726.00
Dec 31, 2016 49,726.00
Dec 31, 2015 73,022.00
Dec 31, 2015 73,022.00